Sept. 15 - Debating booster doses, Aduhelm's slow launch and surging demand for COVID-19 antibodies

Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw.; Departing FDA officials, WHO leaders argue against broad rollout of COVID-19 booster shots; US stocks up on COVID-19 antibody drugs amid shortage concerns; CureVac scales back mRNA manufacturing for coronavirus vaccine View online | Signup | Forward

Commercialization weekly Sept.​ 15,​ 2021 | This week's commercialization news and insights for biopharma leaders New data from Israel, Pfizer show potent effect from third coronavirus shot The much-anticipated data arrive two days before an important FDA advisory meeting to discuss authorization of a booster dose for Pfizer's coronavirus vaccine. Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw. At Morgan Stanley’s healthcare conference last week, executives detailed how the launch of their Alzheimer’s drug has been slower than expected, due in large part to lingering questions about trial data and insurance coverage. Departing FDA officials, WHO leaders argue against broad rollout of COVID-19 booster shots Marion Gruber and Philip Krause, two top FDA vaccine reviewers who are unexpectedly departing this fall, joined senior WHO officials in saying booster vaccine doses are not yet widely needed.  Sponsored Content by FedEx Office Study reveals that print communications are critical for biopharma organizations Have complex information to communicate? Use print to cut through the noise. Learn more in our research infographic. US stocks up on COVID-19 antibody drugs amid shortage concerns Deals with Regeneron and Eli Lilly will secure nearly 1.8 million additional doses of the companies' respective treatments over the next four months. UPDATED CureVac scales back mRNA manufacturing for coronavirus vaccine The German biotech, which announced disappointing results for its shot in June, said the move was done in response to reduced demand.  Read more news The Shifting Data Frontier in Life Sciences Explore the new data frontier in life sciences and real-world case studies of companies that successfully shifted to a new data strategy. Learn More What We're Reading STAT Key senator opposes Democrats’ target for drug pricing savings FiercePharma Bayer pharma goes all-in for digital media buying, moving external operations in-house MM&M Real Chemistry first-half revenue hits $200M Suggest a story we should read Upcoming Events The Benefits of Structured Data for Modern R&D Organizations Sept. 15, 2021 - Sept. 15, 2021 | Webinar 2 pm ET Bring Efficiency and Reproducibility to Biomarker Discovery and Immunophenotyping Studies: Introducing CyTOF XT Sept. 16, 2021 - Sept. 16, 2021 | Webinar 11am ET Life Science Companies: Accelerate Growth with Cloud ERP Sept. 23, 2021 - Sept. 23, 2021 | Webinar 2 pm ET Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Commercialization Weekly with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Commercialization Weekly. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Commercialization Weekly is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip